Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Accelerating IND Timelines with Rapid Gene Synthesis

PROVEN INTELLIGENCE IN AAV VECTOR SYNTHESIS.

Accelerating IND Timelines with Rapid Gene Synthesis for AAV Vectors

CELL & GENE | RNA | BIOLOGICS

Executive Summary

Rapid gene synthesis directly addresses a primary timeline bottleneck in AAV vector production by replacing multi-week plasmid DNA preparation from bacterial cultures with direct chemical synthesis. This accelerates the availability of foundational starting materials, enabling faster, more data-driven preclinical decision-making. The approach supports parallel evaluation of multiple vector candidates, allowing for earlier de-risking of programs targeting a successful IND submission.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

Frequently Asked Questions

How does rapid gene synthesis directly impact AAV vector production timelines for IND-enabling studies?

Rapid gene synthesis decouples vector production from the traditional, often lengthy, process of plasmid DNA preparation from bacterial cultures. By directly synthesizing the required DNA constructs, we can reduce the lead time for necessary starting materials from weeks to days. This acceleration is a key factor in maintaining an 18-24 month timeline to IND submission.

What quality control measures are in place for synthetic DNA used in GxP-compliant AAV vector manufacturing?

All synthetic gene fragments and plasmids undergo rigorous sequence verification via next-generation sequencing (NGS) to confirm 100% accuracy against the target sequence. This eliminates the risk of mutations that can arise during bacterial amplification. This analytical stringency ensures that the resulting AAV vectors are of high quality and integrity, suitable for formal preclinical toxicology programs.

Can rapid AAV vector production facilitate more complex preclinical study designs, such as multi-capsid evaluations?

Yes. The ability to generate multiple vector variants in parallel, each with a different capsid or transgene, allows for more comprehensive early-stage evaluation. This supports data-driven selection of a lead candidate by enabling head-to-head comparisons of transduction efficiency, biodistribution, and expression profiles in relevant in vivo models before committing to a single candidate for IND-enabling toxicology studies.

The direct path to a successful Investigational New Drug (IND) application for AAV-based next-generation therapeutics is influenced by the speed and quality of early vector production. A primary bottleneck in this process has historically been the reliance on conventional plasmid DNA preparation, a multi-week process dependent on bacterial cell culture and amplification.

Rapid, high-fidelity gene synthesis offers a direct solution to this timeline constraint. By moving from biological amplification to direct chemical synthesis of the necessary DNA constructs, development teams can obtain the foundational starting materials for vector production in a fraction of the time. This capability is fundamental to accelerating early research and discovery phases.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Accelerating Preclinical Decision-Making

The strategic advantage of rapid vector synthesis extends beyond simple timeline compression. It enables a more robust and data-driven approach to preclinical development. For instance, understanding how a specific AAV serotype will perform across different species is a key translational challenge. The ability to quickly generate vectors for evaluation allows programs to address potential species-specific discrepancies in expression patterns, a factor that can impact the predictive value of nonhuman primate models (PMID: 21778099).

This speed allows our scientific partners to de-risk their programs earlier and with greater confidence. As one client noted, “This vector release request was followed up in a matter of a few hours and was delivered overnight and ready for use.”

Impact on IND-Enabling Program Design

For a therapeutic program to advance, it must be built on a foundation of analytically sound and reproducible data. Access to rapidly produced, sequence-verified AAV vectors provides the necessary material for definitive go/no-go assessments without introducing delays. This includes material for evaluating the impact of pre-existing neutralizing antibodies on vector transduction efficiency in preclinical models, a known risk factor for clinical translation (PMID: 21476868).

Franklin Biolabs integrates rapid synthesis directly into our AAV production workflow, supporting programs from initial concept through formal preclinical evaluation. This approach is a core component of how our founding scientific leadership and core team have maintained a 100% successful IND rate since 2019, even prior to our formal launch as Franklin Biolabs in 2024. The entire process, from capsid engineering to preclinical safety, is detailed in our expert webinar.

Our work within our >100,000 sq ft facility is designed to provide the vectorology and analytical support needed to navigate the path to a successful FDA submission. This capability is a functional part of our broader Vector | CMC | Analytics Services, which provides a comprehensive framework for advancing next-generation therapeutics.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities